

# United Kingdom Glaucoma Treatment Study (UKGTS) - 2015



## Objective

To evaluate the time to visual field deterioration in primary open-angle glaucoma (POAG) patients given once daily latanoprost compared to POAG patients given placebo.

## Methods

**Design:** Multicenter RCT

**Sample Size:** 516 patients with newly diagnosed POAG

**Treatment Groups:**

- 258 in the latanoprost group
  - 231 at the end of 24 months due to attrition
- 258 in the placebo group
  - 230 at the end of 24 months due to attrition

**Outcome Measures:**

- Primary: Time to visual field deterioration within 24 months.
- Other: Intraocular pressure

## Results

**Point 1:** The time to visual field deterioration was longer in the latanoprost group than the placebo group

- Visual field preservation was significantly longer in the latanoprost group than the placebo group, with an adjusted hazard ratio of 0.44 (95% CI 0.28 – 0.69;  $p = 0.0003$ ).
- Signs of glaucomatous visual field loss were more frequent in the placebo group (25.6% vs. 15.2%,  $p = 0.006$ )

**Point 2:** IOP reduction was greater in the latanoprost group than the placebo group

- At 24 months, mean reduction in IOP was 3.8 mmHg in the latanoprost group ( $n=231$ ) and 0.9 mmHg in the placebo group ( $n=230$ )
- Note that baseline mean IOP was slightly lower in the latanoprost group (19.6 mmHg) than in the placebo group (20.1 mmHg)

**TLDR: Treatment of POAG with latanoprost lowers IOP and preserves visual field function**